when I could see TSBX go beyond USD 2 per stock

**For Turnstone Biologics Corp. (TSBX) to surpass USD 2 per stock, it would require a significant turnaround in its fortunes.** Here's why: 1. **Current Stock Price and Performance**: TSBX is currently trading at $0.48 per share, which is a far cry from the $2 mark. The stock has experienced a significant decline of 85.39% over the past year, making it challenging for the company to recover to its previous levels. 2. **Financial Health Indicators**: TSBX's financial health is under strain, with a gross profit margin of -212.76% and a net income growth rate of -85.39%. These indicators suggest that the company is not profitable and is losing significant amounts of money, which is a tall order to overcome. 3. **Market Sentiment and Analyst Ratings**: The consensus rating for TSBX is "Sell" or worse, indicating that analysts do not see any immediate upside potential for the stock. This sentiment is likely to persist until the company demonstrates significant improvements in its financial performance and clinical development. 4. **Clinical Development and Preclinical Data**: TSBX has made strides in clinical advancement, particularly with its Phase 1 trials for TIDAL-01. However, the company's focus on selected tumor-infiltrating lymphocyte (TIL) therapy is still in the early stages, and it may take time to see significant results that could translate to stock price appreciation. 5. **Strategic Restructuring**: TSBX has undergone a significant restructuring, including workforce reduction and leadership changes, aimed at prioritizing its clinical program and extending the company's cash runway. While these measures may help stabilize the company's financials, they do not guarantee a rapid return to profitability or stock price recovery. 6. **Industry and Sector Performance**: The biotechnology sector is highly competitive and subject to significant regulatory and market challenges. TSBX's ability to navigate these challenges and differentiate itself from competitors will be crucial for any potential stock price appreciation. In conclusion, for TSBX to surpass USD 2 per stock, it would need to demonstrate substantial improvements in its financial performance, clinical development, and market positioning. Given the current indicators and market sentiment, this is a challenging proposition that may take several years to materialize. Investors should be prepared for the potential of continued volatility and possible further declines in the stock price.